3Perrauh G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride:an antipsychotic drug with presynaptic D2/ 1)3 dopamine receptor antagonist activity and limbic selectivity [ J ]. J Pharmacol Exp Ther, 1997,280:73 - 82.
4Scatton B, Claustre Y, Cudennec A, et al. Amisulpride : from animal pharmacology to therapeutic action [ J ]. Int Clin Psychopharmacol, 1997,12(2) :29 -36.
5Rieeardo Torta, Carlotta Berra, Luca Binasehi, Roberto Borio. Amisulpride in the short - term treatment of depressive and physi- cal symptoms in cancer patients during chemotherapies [ J ]. Sup- portive Care in Cancer, 2007,15(5) :579 -581.
7Sparshatt A, Taylor D, Patel MX. Amisulpride - dose, plasmacon- centration, occupancy andresponse : implicationsfor therapeutic drug monitoring[J]. Acta Psychiatr Scand, 2009, 120 (6) :416.
8Farde L, Wiesel FA, Halldin C, et al. Central D2 - dopamine re- ceptor occupancy in schizophrenic patients treated with antipsy- chotic drugs [ J ]. Arch Gen Psychiatry, 1988,45 ( 1 ) :71 - 76.
9Kapur S, Zipursky R, Jones C, et al. Relationship between dopa- mine D2 occupancy, clinical response, and side effects: a double - blind PET study of first episode schizophrenia [ J ]. Am J Psy- chiatry,2000,157 (4) :511 - 520.
10Stefan Leucht, Caroline Corves, Dieter Arbter. Second- genera- tion versus first - generation antipsychotic drugs for schizophrenia:a meta - analysis[J]. Lancet,2009,373:31 -41.
